Printer Friendly

ROBERTS PHARMACEUTICAL ELECTS TWO NEW DIRECTORS

 ROBERTS PHARMACEUTICAL ELECTS TWO NEW DIRECTORS
 EATONTOWN, N.J., May 12 /PRNewswire/ -- Roberts Pharmaceutical


Corporation (NASDAQ: RPCX) announced today that the board of directors increased the number of directors on the board from seven to nine and elected Dr. Toichi Takenaka and Takao Miyamoto, two senior-level executives from Yamanouchi Pharmaceutical Co., Ltd. of Japan, to the Roberts board. The new board members have long and distinguished careers in the pharmaceutical industry.
 Takenaka holds the position of deputy director of Central Research Laboratories and director of Medical Research Laboratories II at Yamanouchi Pharmaceutical Co., Ltd. Since 1991, Takenaka has also served as a visiting professor at the University of Tsukuba, School of Medicine. From 1964 to 1991, Takenaka held various research and management positions at Yamanouchi, including the positions of deputy director of Central Research Laboratories and director of Biomedical Research Laboratories II, from 1990 to 1991, director of Clinical Development Department, from 1989 to 1990, and director of Clinical Research I Office, from 1986 to 1989. Takenaka received a Ph.D. degree from Toho University, School of Medicine, Department of Pharmacology, Japan, and a D.V.M. degree from Gifu University, School of Veterinary Medicine, Japan.
 Miyamoto currently serves as the director of Europe and Americas Department, International Division of Yamanouchi Pharmaceutical Co., Ltd. He has held this international position since 1991. From 1967 to 1991, Miyamoto has held various management positions at Yamanouchi. Miyamoto's recent experience includes that of general manager of the Yamanouchi London office from 1988 to 1991. From 1985 to 1988, Miyamoto served as manager of the marketing function at Yamanouchi's London office. Miyamoto is a graduate of Kyoto University, Pharmaceutical Science, Japan.
 Robert A. Vukovich, Roberts CEO and chairman, stated, "In connection with the recent Yamanouchi $95 million equity investment in Roberts, Roberts had agreed to elect two Yamanouchi representatives to the Roberts board. We are extremely pleased that Yamanouchi has provided two distinguished pharmaceutical executives with outstanding qualifications and experience to serve on our board. We look forward to Dr. Takenaka's and Mr. Miyamoto's active involvement in helping to guide the future growth of Roberts Pharmaceutical."
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non-prescription pharmaceuticals in the United States and abroad.
 -0- 5/12/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: PER


CK-DB -- NY046 -- 9079 05/12/92 11:24 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 12, 1992
Words:444
Previous Article:INTERNATIONAL RESEARCH AND DEVELOPMENT CORP. REPORTS EARNINGS
Next Article:JOHN DEERE CAPITAL $100 MILLION 7.2 PERCENT SENIOR NOTES RATED 'A' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
LIDAK PHARMACEUTICALS ELECTS NEW DIRECTOR
GYNEX PHARMACEUTICALS ANNOUNCES CHANGES IN BOARD OF DIRECTORS, CONTINUED OPERATIONAL ADVANCES
ICN AND SUBSIDIARY COMPANIES ANNOUNCE MANAGEMENT APPOINTMENTS
ROBERTS PHARMACEUTICAL CORPORATION ELECTS NEW DIRECTOR
ROBERTS PHARMACEUTICAL CORPORATION APPOINTS VICE PRESIDENT, DEVELOPMENTAL THERAPEUTICS
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES APPOINTMENT OF NEW GENERAL MANAGER OF CANADIAN SUBSIDIARY
ROBERTS PHARMACEUTICAL CORPORATION ELECTS TWO NEW DIRECTORS
ROBERTS PHARMACEUTICAL CORPORATION NAMES FORMER CHIEF EXECUTIVE OF BOEHRINGER-INGELHEIM (USA), D.W. BARRIOS, TO ROBERTS BOARD OF DIRECTORS
ROBERTS PHARMACEUTICAL CORPORATION CREATES THE POSITION OF WORLDWIDE SALES AND MARKETING AND ANNOUNCES MANAGEMENT ADDITIONS
Roberts Pharmaceutical Corporation Announces Decision of Its Founder to Retire.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters